Risk Insights – Vol. 19, No. 4 – Summary
Issue: December 2015 |
L/H General Industry,
By Karin Brendel, Life/Health Head of Products & Analytics, Cologne
Bernhard Wolters, Life/Health Senior Account Executive, Cologne
Dr. Wolfgang Droste, Consultant, Hong Kong
Jianbo Xiang, Senior Actuary, Hong Kong
Cancer Diagnostics 2.0 – What Does it Mean for Insurers?
by Karin Neelsen
Gen :Re has conducted research within the medical community to understand the implications of new approaches to cancer diagnostics. The emerging technology – commonly referred to as “liquid biopsy” – has implications for insurers, especially in Critical Illness products where protection against cancer plays such an important part.
Dread Disease Survey 2008-2012 – A Snapshot
by Jianbo Xiang and Wolfgang Droste
Gen Re has been studying the Dread Disease market since the mid-1990s. The work has yielded important insights into the emerging experience and the risks associated with this popular and versatile product. This article provides a snapshot of the results of the most recent Dread Disease Survey.
The Risk of Change
by Bernhard Wolters
Insurers typically distinguish between three types of risk: volatility, change and error. Changes in risk factors can influence claims duration and severity. To be successful in insurance requires close monitoring of risk factors and this needs experience, expertise and judgment – qualities that form the backbone of Gen Re's services of our clients.